Schedule & Agenda

With the volatility of public markets in 2022, many companies have considered additional raises…

Immuno-oncology therapies have revolutionized the treatment of many cancers over the last decade,…

According to GBI-Healthcare data, Chinese biotechs entered into 46 out-licensing deals and 160 in…

Atlas Venture reports in its 2022 Year in Review, there are "7000 drugs in clinical development…

With more than $500 billion flowing into ESG-focused funds over the past year, this fastest growing…

With biotechnology stock index values dipping 20% across the past year and IPO volume down more…

The last five years have been challenging for pain R&D. A new study from BIO found that 77% of…

With the passage of the U.S. Inflation Reduction Act in August, biopharma companies must consider…

In 2012, the creation of CRISPR-Cas9 revolutionized gene therapy research by providing a multi…

The most recent FDA reauthorization legislation continues to support thoughtful expansion of real…

An Alliance Bernstein report cites the potential economic impact of synthetic biology in healthcare…

Supply chain shortages, rising costs, changes in the workforce, and continued macroeconomic…

Despite softening valuations among public biotechs and a major tightening of post-series B private…